Cumberland Pharmaceuticals Inc. - Common Stock (CPIX)

NEW YORK CITY, NY / ACCESS Newswire / November 5, 2026 / Cumberland Pharmaceuticals (NASDAQ:CPIX) shareholders lost almost 48.8% of their investment on October 26, 2026, after the Company reported that its Phase 2a ASSIST-SSc pilot study of ifetroban did not produce a clear efficacy signal. If you suffered a loss on your Cumberland Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cumberland Pharmaceuticals Inc. (“Cumberland” or “the Company”) (NASDAQ: CPIX) for violations of the securities laws.